STATERA BIOPHARMA INC (STAB) Fundamental Analysis & Valuation

NASDAQ:STAB • US8575611046

Current stock price

0.0911 USD
-0.01 (-5.2%)
At close:
0.0918 USD
+0 (+0.77%)
After Hours:

This STAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. STAB Profitability Analysis

1.1 Basic Checks

  • STAB had negative earnings in the past year.
  • In the past year STAB has reported a negative cash flow from operations.
STAB Yearly Net Income VS EBIT VS OCF VS FCFSTAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

  • The profitability ratios for STAB are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
STAB Yearly ROA, ROE, ROICSTAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 2K 4K 6K

1.3 Margins

  • Looking at the Gross Margin, with a value of 70.27%, STAB belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for STAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STAB Yearly Profit, Operating, Gross MarginsSTAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. STAB Health Analysis

2.1 Basic Checks

  • STAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, STAB has more shares outstanding
  • The debt/assets ratio for STAB is higher compared to a year ago.
STAB Yearly Shares OutstandingSTAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
STAB Yearly Total Debt VS Total AssetsSTAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

2.2 Solvency

  • STAB has an Altman-Z score of -22.71. This is a bad value and indicates that STAB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -22.71, STAB is doing worse than 90.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.71
ROIC/WACCN/A
WACC15.86%
STAB Yearly LT Debt VS Equity VS FCFSTAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.05 indicates that STAB may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.05, STAB is doing worse than 96.11% of the companies in the same industry.
  • A Quick Ratio of 0.05 indicates that STAB may have some problems paying its short term obligations.
  • STAB has a Quick ratio of 0.05. This is amonst the worse of the industry: STAB underperforms 96.11% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
STAB Yearly Current Assets VS Current LiabilitesSTAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. STAB Growth Analysis

3.1 Past

  • The earnings per share for STAB have decreased strongly by -71.12% in the last year.
  • Looking at the last year, STAB shows a very strong growth in Revenue. The Revenue has grown by 1459.13%.
  • The Revenue for STAB have been decreasing by -15.82% on average. This is quite bad
EPS 1Y (TTM)-71.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.83%
Revenue 1Y (TTM)1459.13%
Revenue growth 3Y9.32%
Revenue growth 5Y-15.82%
Sales Q2Q%183.47%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
STAB Yearly Revenue VS EstimatesSTAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M
STAB Yearly EPS VS EstimatesSTAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 0.1 0.2 0.3 0.4 0.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. STAB Valuation Analysis

4.1 Price/Earnings Ratio

  • STAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STAB Price Earnings VS Forward Price EarningsSTAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STAB Per share dataSTAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. STAB Dividend Analysis

5.1 Amount

  • STAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

STAB Fundamentals: All Metrics, Ratios and Statistics

STATERA BIOPHARMA INC

NASDAQ:STAB (1/11/2023, 8:00:02 PM)

After market: 0.0918 +0 (+0.77%)

0.0911

-0.01 (-5.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)03-29
Inst Owners0%
Inst Owner Change-100%
Ins Owners0.51%
Ins Owner Change0%
Market Cap4.98M
Revenue(TTM)3.69M
Net Income(TTM)-91.83M
Analysts0
Price TargetN/A
Short Float %0.17%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.07
BVpS-0.19
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.27%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -22.71
F-Score3
WACC15.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1459.13%
Revenue growth 3Y9.32%
Revenue growth 5Y-15.82%
Sales Q2Q%183.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1095.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1088.09%
OCF growth 3YN/A
OCF growth 5YN/A

STATERA BIOPHARMA INC / STAB Fundamental Analysis FAQ

What is the fundamental rating for STAB stock?

ChartMill assigns a fundamental rating of 1 / 10 to STAB.


What is the valuation status of STATERA BIOPHARMA INC (STAB) stock?

ChartMill assigns a valuation rating of 0 / 10 to STATERA BIOPHARMA INC (STAB). This can be considered as Overvalued.


How profitable is STATERA BIOPHARMA INC (STAB) stock?

STATERA BIOPHARMA INC (STAB) has a profitability rating of 1 / 10.


Can you provide the financial health for STAB stock?

The financial health rating of STATERA BIOPHARMA INC (STAB) is 0 / 10.